BP Targets Across CKM Stages

• by Kathryn Wighton

• February 19, 2026

FDA approves hepcidin mimetic for PV

Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.

• by Kathryn Wighton

• August 31, 2026

• 3 min

Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines

• by Charlie Zhong, Sidney M Donzella, Erika Rees-Punia

• September 9, 2026

When Heart Failure Treatment Isn’t Enough: Signs It’s Time to Refer for Advanced Heart Failure Care

Advanced heart failure does not always present as a single defining event. Referring physicians may instead notice a pattern of worsening symptoms, recurrent hospitalizations or increasing difficulty maintaining a patient’s clinical stability.

• by

• August 28, 2026

• 6 min